Atypical Protein Kinase C in Neurodegenerative Disease II: PKCι/λ in Tauopathies and α-Synucleinopathies
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To study the role of atypical protein kinase C (aPKC) in neurodegenerative disease, we investigated the distribution of PKCiota/lambda, an aPKC isoform, in a variety of tauopathies and alpha-synucleinopathies. Immunohistochemical study revealed PKCiota/lambda within tau-positive neurofibrillary inclusions in Alzheimer disease (AD), progressive supranuclear palsy, corticobasal degeneration (CBD), and Pick disease (PiD), within alpha-synuclein-positive Lewy bodies in idiopathic Parkinson disease and dementia with Lewy bodies, as well as within glial inclusions in multisystem atrophy. We also observed PKCiota/lambda label of actin-rich Hirano bodies in AD, PiD, and elderly individuals. Double immunolabeling and fluorescence resonance energy transfer demonstrated close physical association between PKCiota/lambda and phospho-tau or alpha-synuclein in some neurofibrillary tangles and Lewy bodies. Furthermore, PKCiota/lambda colocalized with p62, a chaperone protein that binds to both aPKC and ubiquitin, in most of these inclusions. PKCiota/lambda also closely associated with the inactivated form of glycogen synthase kinase-3beta, GSK-3beta[ser9]. Together, these findings suggest that PKCiota/lambda may play a role in common mechanisms involving the pathogenesis of neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 1×
“For example, ubiquitin is abundant in both tau- and >-synuclein-related inclusions (9), and malfunction of the ubiquitinYproteasome system has been implicated in inclusion formation, especially in the formation of Lewy bodies (10).”
BackgroundOffice of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 2×
“The 5 cases of CBD, previously published (7), met current neuropathologic criteria for this disorder (1) with abundant tau-immunoreactive lesions, including astrocytic plaques, degeneration of cortex and nigra, and neurofilament protein-positive ballooned neurons.”
BackgroundSelf-citationMicroscopic analysis of polymerization dynamics with individual actin filaments
Fujiwara, I., Takahashi, S., Tadakuma, H., Funatsu, T., & Ishiwata, S. (2002) · Nature Cell Biology · doi:10.1038/ncb841 · Cited by 420
Papp, M. I., & Lantos, P. L. (1994) · Brain · doi:10.1093/brain/117.2.235 · Cited by 389 · cited 1×
“The classic ubiquitin and >-synuclein-positive but taunegative glial cytoplasmic inclusions within oligodendroglial cells (33) were found in all 3 cases.”
BackgroundRelationships between Lewy bodies and pale bodies in Parkinson's disease
Dale, G. E., Probst, A., Luthert, P., Martin, J., Anderton, B. H., & Leigh, P. N. (1992) · Acta Neuropathologica · doi:10.1007/bf00310030 · Cited by 114 · cited 2×
“For example, Bpale[ Lewy bodies, often regarded as precursors to classic Lewy bodies (39), exhibit diffuse labeling by both PKCI/L and >synuclein, whereas classic Lewy bodies exhibit disparate localization of the 2 molecules.”
Background
Cited by
Neuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“…(MPTP) model of parkinsonism (Duka et al. 2006), and the co-location of phospho-tau and aSyn in both NFTs and LBs (Ishizawa et al. 2003; Shao et al. 2006) and the co-occurrence of abnormal deposition of tau, aSyn and TDP-43 in AD, DLB and other NDDs, probably related to genetic factors…”
BackgroundPrevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0347-5 · Cited by 268
Metadata
- Authors
- Shao, C. Y., Crary, J. F., Rao, C., Sacktor, T. C., & Mirra, S. S.
- Venue
- Journal of Neuropathology and Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04
- Volume
- 65
- Issue
- 4
- Pages
- 327-335
- ISSN
- 0022-3069 (ISSN-L)
- OpenAlex
- W2000653725
- Cited by
- 45
- References
- 5
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atypical Protein Kinase C in Neurodegenerative Disease II: PKCι/λ in Tauopathies and α-Synucleinopathies. https://app.cochat.ai/papers/10.1097/01.jnen.0000218441.00040.82
- The paper
- Shao, C. Y., Crary, J. F., Rao, C., Sacktor, T. C., & Mirra, S. S. (2006). Atypical Protein Kinase C in Neurodegenerative Disease II: PKCι/λ in Tauopathies and α-Synucleinopathies. Journal of Neuropathology and Experimental Neurology. https://doi.org/10.1097/01.jnen.0000218441.00040.82
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.